New R&D leader at BMS

pharmafield logo - pharma news

Pharma Appointment Bristol-Myers Squibb has appointed a new Executive Vice President and Chief Scientific Officer after Dr Elliott Sigal announced his retirement from both positions at the end of June.

The experienced Dr Francis Cuss has been selected to fill both roles after serving in a number of senior appointments since he joined the company in 2003.

Lamberto Andreotti, BMS CEO, said Dr Cuss is a “strong and collaborative leader with broad experience” and now is a “natural time” for him to lead the company’s R&D team.

The new R&D leader said he was “honoured” to lead the “talented R&D team to fulfil our mission and find new ways to discover, develop and deliver innovative medicines for patients with unmet medical needs.”

He first joined the company a decade ago as Senior Vice President for Drug Discovery. He later went on to take responsibility for Discovery Medicine and Clinical Pharmacology and was appointed a member of the company’s senior management team three years ago.

The retiring Dr Sigal first joined BMS in 1997 as Vice President of the newly created department of Applied Genomics. He has been a member of the senior management team since 2001 and became Executive Vice President five years later. He was also elected to the board of directors in 2011.

“Elliott has been a key leader in the development and execution of our company’s strategy to become a BioPharma leader,” said Lamberto Andreotti. “He and his team have become one of the most productive and innovative R&D organisations in the industry. I am grateful for the many things that Elliott and I have been able to accomplish together.”